Geneos Wealth Management’s Celldex Therapeutics CLDX Stock Holding History

Geneos Wealth Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,333	Closed	-$51K	–	2785
2021 Q4	$51K	Hold	1,333	–	–	﹤0.01%	1463
2021 Q3	$74K	Hold	1,333	–	–	﹤0.01%	1294
2021 Q2	$45K	Hold	1,333	–	–	﹤0.01%	1529
2021 Q1	$40K	Hold	1,333	–	–	﹤0.01%	1738
2020 Q4	$27K	Hold	1,333	–	–	﹤0.01%	1743
2020 Q3	$17K	Hold	1,333	–	–	﹤0.01%	1721
2020 Q2	$16K	Hold	1,333	–	–	﹤0.01%	1714
2020 Q1	$2K	Hold	1,333	–	–	﹤0.01%	2238
2019 Q4	$2K	Hold	1,333	–	–	﹤0.01%	2358
2019 Q3	$2K	Hold	1,333	–	–	﹤0.01%	2288
2019 Q2	$3K	Hold	1,333	–	–	﹤0.01%	2208
2019 Q1	$6K	Buy	+1,333	New	+$7.01K	﹤0.01%	1979

Other funds holding CLDX

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return